论文部分内容阅读
目的:观察替比夫定联合扶正化瘀胶囊治疗慢性乙型病毒性肝炎纤维化的疗效。方法:将60例乙型病毒性肝炎患者(存在肝纤维化)随机分为治疗组和对照组。治疗组采用替比夫定和扶正化瘀胶囊治疗;对照组采用替比夫定治疗,疗程均为48周。观察两组治疗前后疗效、肝功、肝纤维化指标、B超指标及DNA定量变化。结果:治疗组治疗后肝功能及肝纤维化指标(HA、Ⅳ-C)均有所改善(P<0.05);脾脏厚度明显缩小(P<0.05),门静脉和脾静脉内径较对照组缩小,但无统计学意义(P>0.05);治疗后治疗组HBV-DNA转阴率为46%,E抗原转换率为38%,对照组分别为41%、36%,治疗组上述指标略高于对照组,但无统计学意义(P>0.05)。结论:替比夫定联合扶正化瘀胶囊治疗,能够通过抑制病毒和抗纤维化,明显改善乙型病毒性肝炎纤维化患者的病情和预后。
Objective: To observe the curative effect of telbivudine combined with Fuzhenghuayu Capsule on chronic hepatitis B virus fibrosis. Methods: Sixty patients with hepatitis B (with liver fibrosis) were randomly divided into treatment group and control group. The treatment group treated with telbivudine and Fuzhenghuayu capsule; the control group treated with telbivudine, the course of treatment were 48 weeks. The curative effect, liver function, liver fibrosis index, B-ultrasound index and DNA quantitative change of the two groups were observed before and after treatment. Results: The liver function, hepatic fibrosis indexes (HA and Ⅳ-C) of the treatment group were improved (P <0.05), the spleen thickness was significantly reduced (P <0.05), the diameter of the portal vein and splenic vein was smaller than that of the control group, But no statistical significance (P> 0.05). After treatment, the HBV-DNA negative rate was 46% and the E antigen conversion rate was 38% in treatment group and 41% and 36% in control group respectively. The above indexes in treatment group were slightly higher than those in control group Control group, but not statistically significant (P> 0.05). Conclusion: Telbivudine combined with Fuzhenghuayu Capsule can significantly improve the disease and prognosis of patients with hepatitis B fibrosis by inhibiting the virus and anti-fibrosis.